ICC Labs Enters Sale Agreement for CBD Products to Nuuvera

Cannabis Investing News

ICC Labs announced its subsidiary Tersum S.A. will export CBD crystal to a subsidiary of Nuuvera, Avanti Rx Analytics.

ICC Labs (TSXV:ICC) announced its subsidiary Tersum S.A. will export cannabidiol (CBD) crystal to a subsidiary of Nuuvera (TSXV:NUU), Avanti Rx Analytics.
As quoted in the press release:

Avanti holds a dealer licence under the Controlled Drugs and Substances Act (Canada) and its regulations overseen by Health Canada.
“We are pleased to enter into this sale agreement with Nuuvera and look forward to establishing an important relationship with significant Canadian players in the cannabis space,” commented Alejandro Antalich, Chief Executive Officer of ICC Lab. “This agreement further validates our Active Pharmaceutical Ingredient (“API“) platform on an international scale and positions ICC Labs for additional distribution opportunities. ICC Labs expects to produce its API’s under the Good Manufacturing Practices (“GMP“) regulations and guidelines to ensure product specifications, safety and consistent efficacy. The sale and export to Avanti will increase our presence in the Canadian market.”

Click here to read the full press release.

Source: www.weednewswire.com

The Conversation (0)
×